ArticleJournal of inflammation (London, England)2012
The pro-atherogenic effects of macrophages are reduced upon formation of a complex between C-reactive protein and lysophosphatidylcholine.
Article in Journal of inflammation (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Changes in Choline Metabolites and Ceramides in Response to a DASH-Style Diet in Older Adults.Nutrients · 2023Trial
- Identification of plasma lipid metabolism and potential biomarkers in patients with different coronary occlusive acute myocardial infarction.Frontiers in cell and developmental biology · 2025Article
- Plasma lipidomic alterations during pathogenic SIV infection with and without antiretroviral therapy.Frontiers in immunology · 2025Article
- Comparison of Adiposomal Lipids between Obese and Non-Obese Individuals.Metabolites · 2024Article
- Multinomial machine learning identifies independent biomarkers by integrated metabolic analysis of acute coronary syndrome.Scientific reports · 2023Article
- C-Reactive Protein in Atherosclerosis-More than a Biomarker, but not Just a Culprit.Reviews in cardiovascular medicine · 2023Review
- C-Reactive Protein Signaling Pathways in Tumor Progression.Biomolecules & therapeutics · 2023Review
- Plasma Lipidomic Subclasses and Risk of Hypertension in Middle-Aged and Elderly Chinese.Phenomics (Cham, Switzerland) · 2022Article
- An Updated Review of Pro- and Anti-Inflammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System.International journal of molecular sciences · 2020Review
- Functionality of C-Reactive Protein for Atheroprotection.Frontiers in immunology · 2019Review
- Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism.Molecular and cellular biochemistry · 2018Article
- C-Reactive Protein in Atherothrombosis and Angiogenesis.Frontiers in immunology · 2018Review
- The combination of CRP isoforms with oxLDL decreases TNF-α and IL-6 release by U937-derived macrophages.Biomedical reports · 2017Article
- Functional Transformation of C-reactive Protein by Hydrogen Peroxide.The Journal of biological chemistry · 2017Article
- Phosphocholine-containing ligands direct CRP induction of M2 macrophage polarization independent of T cell polarization: Implication for chronic inflammatory states.Immunity, inflammation and disease · 2016Article
- Recognition functions of pentameric C-reactive protein in cardiovascular disease.Mediators of inflammation · 2014Review
- Advanced oxidation protein products induce cardiomyocyte death via Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK signaling.Free radical biology & medicine · 2013Article
- Probing the phosphocholine-binding site of human C-reactive protein by site-directed mutagenesis.The Journal of biological chemistry · 1992Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RATIONALE: C-reactive protein (CRP) and lysophosphatidylcholine (LPC) are phosphorylcholine-(PC)-containing oxidized phospholipids (oxPLs) found in oxidized LDL (oxLDL), which trigger pro-atherogenic activities of macrophages during the process of atherosclerosis. It has been previously reported that CRP binds to the PC head group of oxLDL in a calcium-dependent manner. The aim of this study was to investigate the importance of binding between CRP and LPC to the pro-atherogenic activities of macrophages. OBJECTIVES AND
findingsA chemiluminescent immunoassay and HPLC showed that human recombinant CRP formed a stable complex with LPC in the presence of calcium. The Kd value of the binding of the CRP-LPC complex to the receptors FcγRIA or FcγRIIA was 3-5 fold lower than that of CRP alone. The CRP-LPC complex triggered less potent generation of reactive oxygen species and less activation of the transcription factors AP-1 and NF-kB by human monocyte-derived macrophages in comparison to CRP or LPC alone. However, CRP did not affect activities driven by components of oxLDL lacking PC, such as upregulation of PPRE, ABCA1, CD36 and PPARγ and the enhancement of cholesterol efflux by human macrophages. The presence of CRP inhibited the association of Dil-labelled oxLDL to human macrophages.
conclusionsThe formation of complexes between CRP and PC-containing oxPLs, such as LPC, suppresses the pro-atherogenic effects of CRP and LPC on macrophages. This effect may in part retard the progression of atherosclerosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.